Source: Annual Congress 2012 - New insights in pneumology - ERS inter-Assemblies late-breaking abstracts
Disease area: Airway diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
D. Garcha, S. Thurston, A. Patel, A. Mackay, J. Goldring, T. McHugh, G. Donaldson, J. Wedzicha (London, United Kingdom). LATE-BREAKING ABSTRACT: Association of airway bacterial load with inhaled corticosteroid dosage in stable COPD. Eur Respir J 2012; 40: Suppl. 56, 2741

Member's Comments

No comment yet.

Related content which might interest you: LATE-BREAKING ABSTRACT: Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD patients Source: International Congress 2015 – Infection in COPD: different aspects of the host/pathogen balance Year: 2015 LATE-BREAKING ABSTRACT: Blood eosinophils (EOS) are a biomarker of COPD exacerbation reduction with inhaled corticosteroids (ICS): An across-trials model-based approach Source: International Congress 2016 – New and old therapies for chronic lung diseases Year: 2016 Are inhaled corticosteroids increasing the “load” for some patients with COPD? Source: Eur Respir J, 50 (4) 1701848; 10.1183/13993003.01848-2017 Year: 2017 LATE-BREAKING ABSTRACT: Evaluating blood eosinophils and exacerbation history to predict ICS response in COPD Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016 LATE-BREAKING ABSTRACT: Glycopyrronium once-daily significantly improves lung function and health status when added to fluticasone/salmeterol in patients with COPD: The GLISTEN study Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 LATE-BREAKING ABSTRACT: Outcome of withdrawal of one inhaler in COPD patients received combined ICS/LABA and LAMA Source: International Congress 2014 – Latest insights in airway diseases Year: 2014 Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001 Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD Source: Eur Respir J, 50 (4) 1700451; 10.1183/13993003.00451-2017 Year: 2017 LATE-BREAKING ABSTRACT: The novel inhaled dual PDE3/4 inhibitor RPL554 produces significant additional improvements in lung function when administered on top of existing standard of care in COPD patients Source: International Congress 2016 – Late-breaking topics in airways disease Year: 2016 The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment Source: Eur Respir J 2006; 27: 964-971 Year: 2006 The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids Source: Eur Respir J, 49 (6) 1700848; 10.1183/13993003.00848-2017 Year: 2017 Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids Source: Eur Respir J 2017; 49(1): 1600839; DOI: 10.1183/13993003.00839-2016 Year: 2017 Dose response for inhaled fluticasone on airway and systemic inflammation in COPD Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Dose–response for inhaled fluticasone on airway and systemic inflammation in COPD Source: Eur Respir J 2011; 37: 206-209 Year: 2011 Effect of switching from high-dose inhaled corticosteroid (ICS) to low-dose ICS plus an inhaled long-acting β2-agonist on asthma control, airway inflammation and remodeling, and gene expression in airway epithelial cells Source: Eur Respir J 2003; 22: Suppl. 45, 35s Year: 2003 Comparison of budesonide and fluticasone propionate on COPD macrophage phagocytosis and killing of bacteria Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 Budesonide and formoterol in a single inhaler controls exacerbations more effectively than a higher dose of inhaled corticosteroids alone, in mild-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 43s Year: 2001 LATE-BREAKING ABSTRACT: Effects of a fixed dose once-daily triple drug combination in smokers and non-smokers with COPD Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016